Geron Corporation (GERN) 2.75 $GERN
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 5.54 (-0.08), ALNY: 63.46 (+1.28), GERN: 2.75 (+0.03), CYTR: 2.51 (+0.25)
Geron (GERN) Q1 Loss In-Line, Imetelstat Remains in Focus
Arpita Dutt - Zacks Investment Research - Fri May 06, 7:18AM CDT
While Geron's (GERN) first quarter loss was in-line with expectations, investor focus remains on imetelstat.
JNJ: 122.93 (+0.08), CBM: 55.01 (+0.85), ANIP: 55.38 (-1.13), GERN: 2.75 (+0.03)
Geron reports 1Q loss
Automated Insights - Thu May 05, 5:44PM CDT
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Thursday reported a loss of $8.8 million in its first quarter.
GERN: 2.75 (+0.03)
Geron Corporation Reports First Quarter 2016 Financial Results and Recent Events
GlobeNewswire - Thu May 05, 3:05PM CDT
Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2016 and recent events.
GERN: 2.75 (+0.03)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.12 (+0.23), BIIB: 252.54 (+1.24), CNAT: 2.21 (+0.02), AMGN: 160.18 (-0.92), RPRX: 1.72 (-0.01), JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30), GWPH: 96.35 (+1.52), GERN: 2.75 (+0.03), AVEO: 0.95 (unch), ICPT: 151.73 (unch), AGIO: 42.50 (-0.25), NVS: 82.31 (+0.18)
Geron (GERN) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:20AM CDT
Investor focus will remain on pipeline updates from Geron (GERN).
JNJ: 122.93 (+0.08), OVAS: 5.45 (-0.21), GERN: 2.75 (+0.03), JAZZ: 140.16 (+0.28)
Geron Announces Conference Call to Discuss First Quarter 2016 Financial Results
GlobeNewswire - Wed Apr 27, 6:30AM CDT
Geron Corporation (Nasdaq:GERN) will announce its financial results for the first quarter ended March 31, 2016, on Thursday, May 5, 2016, after the market close. Geron's management will also host a conference call for analysts and investors on Thursday, May 5, 2016, at 4:30 p.m. Eastern Time to discuss the company's first quarter results and events.
GERN: 2.75 (+0.03)
Are These 3 Biotechs Destined to Be Bought Out?
George Budwell, The Motley Fool - Motley Fool - Sun Apr 24, 1:59PM CDT
The merger and acquisition frenzy that's been spreading across the biotech landscape over the last few years might be about to hit fever pitch. After all, heavyweights like Allergan , Gilead Sciences , Celgene Corp. , Johnson & Johnson ,...
CPXX: 30.24 (unch), JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30), GERN: 2.75 (+0.03), JUNO: 27.33 (-0.48), CELG: 103.41 (-1.62)
Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting
GlobeNewswire - Wed Apr 20, 6:30AM CDT
Geron Corporation (Nasdaq:GERN) today announced two poster presentations of data from non-clinical studies of the telomerase inhibitor, imetelstat, at the 2016 American Association for Cancer Research (AACR) Annual Meeting held in New Orleans, Louisiana. The first poster presentation described results that treating acute myeloid leukemia (AML) cell lines with imetelstat enhanced the effects of agents currently used for the treatment of AML. These data extend the rationale from prior non-clinical studies for the potential use of imetelstat in hematologic myeloid malignancies, such as AML, including in combination with standard therapies. The second poster presentation described results from non-clinical studies that provide further evidence of potential on-target mechanisms of telomerase inhibition by imetelstat underlying the reduction in platelets observed in previously conducted imetelstat clinical trials.
GERN: 2.75 (+0.03)
Geron to Present at the Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 15th Annual Needham Healthcare Conference in New York at 8:40 a.m. Eastern Time on Tuesday, April 12, 2016.
GERN: 2.75 (+0.03)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 11.09 (-0.10), CMRX: 3.93 (-0.06), GERN: 2.75 (+0.03), CYTX: 2.01 (unch), CLDX: 4.57 (-0.07), SGMO: 6.00 (-0.18), PTCT: 7.47 (-0.06), ATHX: 2.32 (+0.03), MNKD: 1.14 (-0.03)
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
SYN: 1.85 (-0.04), GERN: 2.75 (+0.03), EPZM: 10.35 (+0.04), CORT: 6.02 (+0.01)
4 Surging Stocks Brokers Love in the Healthcare Sector
Arpita Dutt - Zacks Investment Research - Mon Mar 28, 8:16AM CDT
These four stocks are holding their own in a sector that has been in the news for the wrong reasons and have surged more than 10% in the last 4 weeks.
JNJ: 122.93 (+0.08), VRX: 23.09 (-0.16), SYN: 1.85 (-0.04), GERN: 2.75 (+0.03), AMGN: 160.18 (-0.92), EPZM: 10.35 (+0.04), CORT: 6.02 (+0.01)
Gilead and 4 Other Buy Stocks in the Biotech Industry
Arpita Dutt - Zacks Investment Research - Tue Mar 22, 8:05AM CDT
Even though the sector is going through tough times, biotech stocks continue to attract a lot of interest.
JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30), GERN: 2.75 (+0.03), LGND: 126.76 (+0.90), AMGN: 160.18 (-0.92), JUNO: 27.33 (-0.48), NVS: 82.31 (+0.18)
3 Biotech Stocks to Buy on Sale
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Mar 18, 7:22AM CDT
Image Source TBIT via pixabay The broad S&P 500 has rallied over the last few weeks, and it has largely recovered from the beating that it took early in the year. The biotech sector, however, hasn't fared quite as well. Many biotech stocks...
AGN: 238.28 (-2.31), GERN: 2.75 (+0.03), PFE: 36.15 (+0.03), IBB: 270.56 (-0.57), CHRS: 21.93 (+4.71)
Geron Announces Presentations at American Association of Cancer Research Annual Meeting
GlobeNewswire - Thu Mar 17, 6:30AM CDT
Geron Corporation (Nasdaq:GERN) today announced that two abstracts describing non-clinical data on imetelstat have been accepted for presentation as posters at the 2016 American Association of Cancer Research (AACR) Annual Meeting to be held in New Orleans, Louisiana from April 16-20, 2016. The abstracts are available on the AACR website at www.aacr.org.
GERN: 2.75 (+0.03)
3 Stocks That Could Make You Rich
Steve Symington, Jason Hall, and George Budwell, The Motley Fool - Motley Fool - Tue Mar 15, 3:30PM CDT
Image source: The Motley Fool. For any investor looking to put money to work in the stock market over the long term, it seems easy to say one of the primary goals is to generate or sustain wealth. But finding the right stocks to do so isn't always...
JNJ: 122.93 (+0.08), SWIR: 17.48 (+0.09), GERN: 2.75 (+0.03), BIP: 46.20 (-0.11)
3 Reasons Geron Corporation Stock Could Rise
Cory Renauer, The Motley Fool - Motley Fool - Tue Mar 08, 3:19PM CST
Image source: Flickr user Chris Potter. Developing and commercializing new cancer therapies is difficult for any organization. For a company as small Geron Corporation (NASDAQ: GERN), it's nearly impossible. Investors nearly lost all hope a...
JNJ: 122.93 (+0.08), GERN: 2.75 (+0.03)
Geron to Present at the RBC Capital Markets Healthcare Conference
GlobeNewswire - Wed Feb 10, 6:30AM CST
Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the RBC Capital Markets 2016 Global Healthcare Conference in New York at 8:30 a.m. Eastern Time on Tuesday, February 23.
GERN: 2.75 (+0.03)
Shares of Incyte Corporation Plummeted in January -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 07, 6:08AM CST
What: Shares of Incyte , a drug developer primarily focused on the development of therapies to treat cancer, plummeted to the tune of 35% in January based on data from S&P Capital IQ . The culprits for the drop were overall market sentiment...
JNJ: 122.93 (+0.08), GERN: 2.75 (+0.03), INCY: 85.00 (-0.70)
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 5.54 (-0.08), ALNY: 63.46 (+1.28), GERN: 2.75 (+0.03), CYTR: 2.51 (+0.25)
Geron (GERN) Q1 Loss In-Line, Imetelstat Remains in Focus
Arpita Dutt - Zacks Investment Research - Fri May 06, 7:18AM CDT
While Geron's (GERN) first quarter loss was in-line with expectations, investor focus remains on imetelstat.
JNJ: 122.93 (+0.08), CBM: 55.01 (+0.85), ANIP: 55.38 (-1.13), GERN: 2.75 (+0.03)
Geron reports 1Q loss
Automated Insights - Thu May 05, 5:44PM CDT
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Thursday reported a loss of $8.8 million in its first quarter.
GERN: 2.75 (+0.03)
Geron Corporation Reports First Quarter 2016 Financial Results and Recent Events
GlobeNewswire - Thu May 05, 3:05PM CDT
Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2016 and recent events.
GERN: 2.75 (+0.03)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.12 (+0.23), BIIB: 252.54 (+1.24), CNAT: 2.21 (+0.02), AMGN: 160.18 (-0.92), RPRX: 1.72 (-0.01), JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30), GWPH: 96.35 (+1.52), GERN: 2.75 (+0.03), AVEO: 0.95 (unch), ICPT: 151.73 (unch), AGIO: 42.50 (-0.25), NVS: 82.31 (+0.18)
Geron (GERN) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:20AM CDT
Investor focus will remain on pipeline updates from Geron (GERN).
JNJ: 122.93 (+0.08), OVAS: 5.45 (-0.21), GERN: 2.75 (+0.03), JAZZ: 140.16 (+0.28)
Geron Announces Conference Call to Discuss First Quarter 2016 Financial Results
GlobeNewswire - Wed Apr 27, 6:30AM CDT
Geron Corporation (Nasdaq:GERN) will announce its financial results for the first quarter ended March 31, 2016, on Thursday, May 5, 2016, after the market close. Geron's management will also host a conference call for analysts and investors on Thursday, May 5, 2016, at 4:30 p.m. Eastern Time to discuss the company's first quarter results and events.
GERN: 2.75 (+0.03)
Are These 3 Biotechs Destined to Be Bought Out?
George Budwell, The Motley Fool - Motley Fool - Sun Apr 24, 1:59PM CDT
The merger and acquisition frenzy that's been spreading across the biotech landscape over the last few years might be about to hit fever pitch. After all, heavyweights like Allergan , Gilead Sciences , Celgene Corp. , Johnson & Johnson ,...
CPXX: 30.24 (unch), JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30), GERN: 2.75 (+0.03), JUNO: 27.33 (-0.48), CELG: 103.41 (-1.62)
Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting
GlobeNewswire - Wed Apr 20, 6:30AM CDT
Geron Corporation (Nasdaq:GERN) today announced two poster presentations of data from non-clinical studies of the telomerase inhibitor, imetelstat, at the 2016 American Association for Cancer Research (AACR) Annual Meeting held in New Orleans, Louisiana. The first poster presentation described results that treating acute myeloid leukemia (AML) cell lines with imetelstat enhanced the effects of agents currently used for the treatment of AML. These data extend the rationale from prior non-clinical studies for the potential use of imetelstat in hematologic myeloid malignancies, such as AML, including in combination with standard therapies. The second poster presentation described results from non-clinical studies that provide further evidence of potential on-target mechanisms of telomerase inhibition by imetelstat underlying the reduction in platelets observed in previously conducted imetelstat clinical trials.
GERN: 2.75 (+0.03)
Geron to Present at the Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 15th Annual Needham Healthcare Conference in New York at 8:40 a.m. Eastern Time on Tuesday, April 12, 2016.
GERN: 2.75 (+0.03)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 11.09 (-0.10), CMRX: 3.93 (-0.06), GERN: 2.75 (+0.03), CYTX: 2.01 (unch), CLDX: 4.57 (-0.07), SGMO: 6.00 (-0.18), PTCT: 7.47 (-0.06), ATHX: 2.32 (+0.03), MNKD: 1.14 (-0.03)
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
SYN: 1.85 (-0.04), GERN: 2.75 (+0.03), EPZM: 10.35 (+0.04), CORT: 6.02 (+0.01)
4 Surging Stocks Brokers Love in the Healthcare Sector
Arpita Dutt - Zacks Investment Research - Mon Mar 28, 8:16AM CDT
These four stocks are holding their own in a sector that has been in the news for the wrong reasons and have surged more than 10% in the last 4 weeks.
JNJ: 122.93 (+0.08), VRX: 23.09 (-0.16), SYN: 1.85 (-0.04), GERN: 2.75 (+0.03), AMGN: 160.18 (-0.92), EPZM: 10.35 (+0.04), CORT: 6.02 (+0.01)
Gilead and 4 Other Buy Stocks in the Biotech Industry
Arpita Dutt - Zacks Investment Research - Tue Mar 22, 8:05AM CDT
Even though the sector is going through tough times, biotech stocks continue to attract a lot of interest.
JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30), GERN: 2.75 (+0.03), LGND: 126.76 (+0.90), AMGN: 160.18 (-0.92), JUNO: 27.33 (-0.48), NVS: 82.31 (+0.18)
3 Biotech Stocks to Buy on Sale
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Mar 18, 7:22AM CDT
Image Source TBIT via pixabay The broad S&P 500 has rallied over the last few weeks, and it has largely recovered from the beating that it took early in the year. The biotech sector, however, hasn't fared quite as well. Many biotech stocks...
AGN: 238.28 (-2.31), GERN: 2.75 (+0.03), PFE: 36.15 (+0.03), IBB: 270.56 (-0.57), CHRS: 21.93 (+4.71)
Geron Announces Presentations at American Association of Cancer Research Annual Meeting
GlobeNewswire - Thu Mar 17, 6:30AM CDT
Geron Corporation (Nasdaq:GERN) today announced that two abstracts describing non-clinical data on imetelstat have been accepted for presentation as posters at the 2016 American Association of Cancer Research (AACR) Annual Meeting to be held in New Orleans, Louisiana from April 16-20, 2016. The abstracts are available on the AACR website at www.aacr.org.
GERN: 2.75 (+0.03)
3 Stocks That Could Make You Rich
Steve Symington, Jason Hall, and George Budwell, The Motley Fool - Motley Fool - Tue Mar 15, 3:30PM CDT
Image source: The Motley Fool. For any investor looking to put money to work in the stock market over the long term, it seems easy to say one of the primary goals is to generate or sustain wealth. But finding the right stocks to do so isn't always...
JNJ: 122.93 (+0.08), SWIR: 17.48 (+0.09), GERN: 2.75 (+0.03), BIP: 46.20 (-0.11)
3 Reasons Geron Corporation Stock Could Rise
Cory Renauer, The Motley Fool - Motley Fool - Tue Mar 08, 3:19PM CST
Image source: Flickr user Chris Potter. Developing and commercializing new cancer therapies is difficult for any organization. For a company as small Geron Corporation (NASDAQ: GERN), it's nearly impossible. Investors nearly lost all hope a...
JNJ: 122.93 (+0.08), GERN: 2.75 (+0.03)
Geron to Present at the RBC Capital Markets Healthcare Conference
GlobeNewswire - Wed Feb 10, 6:30AM CST
Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the RBC Capital Markets 2016 Global Healthcare Conference in New York at 8:30 a.m. Eastern Time on Tuesday, February 23.
GERN: 2.75 (+0.03)
Shares of Incyte Corporation Plummeted in January -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 07, 6:08AM CST
What: Shares of Incyte , a drug developer primarily focused on the development of therapies to treat cancer, plummeted to the tune of 35% in January based on data from S&P Capital IQ . The culprits for the drop were overall market sentiment...
JNJ: 122.93 (+0.08), GERN: 2.75 (+0.03), INCY: 85.00 (-0.70)
